BACKGROUND AND PURPOSE: A recent study identified a preprocedural P2Y12 reaction units value of <60 or >240 as a strong independent predictor of perioperative thromboembolic and hemorrhagic complications after treatment of cerebral aneurysms with the Pipeline Embolization Device. This study aimed to determine whether a last-recorded P2Y12 reaction units value of <60 or >240 predicts thromboembolic and hemorrhagic complications up to 6 months after treatment of cerebral aneurysms with the Pipeline Embolization Device in the same patient cohort. MATERIALS AND METHODS: We recorded patient and aneurysm characteristics, P2Y12 receptor antagonist administered, P2Y12 reaction units value with VerifyNow, procedural variables, and thromboembolic and hemorrhagic complications up to 6 months after Pipeline Embolization Device procedures at our institution during an 8-month period. Complications causing a permanent disabling neurologic deficit or death were considered major. Multivariate regression analysis was performed to identify independent predictors of thromboembolic and hemorrhagic complications. RESULTS: Forty-four patients underwent 48 Pipeline Embolization Device procedures at our institution during the study period. There were 11 thromboembolic and hemorrhagic complications up to 6 months after treatment in our cohort (22.9%), 5 of which were major (10.4%). A last-recorded P2Y12 reaction units value of <60 or >240 was the only independent predictor of all (P = .002) and major (P = .03) thromboembolic and hemorrhagic complications in our cohort. Most patients (71%) required, on average, 2 adjustments to the dose or type of P2Y12 receptor antagonist to remain within the 60-240 target P2Y12 reaction units range. CONCLUSIONS: In our cohort, a last-recorded P2Y12 reaction units value of <60 or >240 was the only independent predictor of all and major thromboembolic and hemorrhagic complications up to 6 months after Pipeline Embolization Device procedures.
BACKGROUND AND PURPOSE: A recent study identified a preprocedural P2Y12 reaction units value of <60 or >240 as a strong independent predictor of perioperative thromboembolic and hemorrhagic complications after treatment of cerebral aneurysms with the Pipeline Embolization Device. This study aimed to determine whether a last-recorded P2Y12 reaction units value of <60 or >240 predicts thromboembolic and hemorrhagic complications up to 6 months after treatment of cerebral aneurysms with the Pipeline Embolization Device in the same patient cohort. MATERIALS AND METHODS: We recorded patient and aneurysm characteristics, P2Y12 receptor antagonist administered, P2Y12 reaction units value with VerifyNow, procedural variables, and thromboembolic and hemorrhagic complications up to 6 months after Pipeline Embolization Device procedures at our institution during an 8-month period. Complications causing a permanent disabling neurologic deficit or death were considered major. Multivariate regression analysis was performed to identify independent predictors of thromboembolic and hemorrhagic complications. RESULTS: Forty-four patients underwent 48 Pipeline Embolization Device procedures at our institution during the study period. There were 11 thromboembolic and hemorrhagic complications up to 6 months after treatment in our cohort (22.9%), 5 of which were major (10.4%). A last-recorded P2Y12 reaction units value of <60 or >240 was the only independent predictor of all (P = .002) and major (P = .03) thromboembolic and hemorrhagic complications in our cohort. Most patients (71%) required, on average, 2 adjustments to the dose or type of P2Y12 receptor antagonist to remain within the 60-240 target P2Y12 reaction units range. CONCLUSIONS: In our cohort, a last-recorded P2Y12 reaction units value of <60 or >240 was the only independent predictor of all and major thromboembolic and hemorrhagic complications up to 6 months after Pipeline Embolization Device procedures.
Authors: I Szikora; Z Berentei; Z Kulcsar; M Marosfoi; Z S Vajda; W Lee; A Berez; P K Nelson Journal: AJNR Am J Neuroradiol Date: 2010-02-11 Impact factor: 3.825
Authors: Laurent Bonello; Udaya S Tantry; Rossella Marcucci; Ruediger Blindt; Dominick J Angiolillo; Richard Becker; Deepak L Bhatt; Marco Cattaneo; Jean Philippe Collet; Thomas Cuisset; Christian Gachet; Gilles Montalescot; Lisa K Jennings; Dean Kereiakes; Dirk Sibbing; Dietmar Trenk; Jochem W Van Werkum; Franck Paganelli; Matthew J Price; Ron Waksman; Paul A Gurbel Journal: J Am Coll Cardiol Date: 2010-09-14 Impact factor: 24.094
Authors: Josser E Delgado Almandoz; Benjamin M Crandall; Jill M Scholz; Jennifer L Fease; Ruth E Anderson; Yasha Kadkhodayan; David E Tubman Journal: J Neurointerv Surg Date: 2013-01-12 Impact factor: 5.836
Authors: Christoph Varenhorst; Stefan James; David Erlinge; Oscar O Braun; John T Brandt; Kenneth J Winters; Joseph A Jakubowski; Sylvia Olofsson; Lars Wallentin; Agneta Siegbahn Journal: Am Heart J Date: 2009-02-06 Impact factor: 4.749
Authors: Young-Hoon Jeong; Kevin P Bliden; Mark J Antonino; Ki-Soo Park; Udaya S Tantry; Paul A Gurbel Journal: Am Heart J Date: 2012-06-13 Impact factor: 4.749
Authors: S Hassan Akbari; Matthew R Reynolds; Yasha Kadkhodayan; Dewitte T Cross; Christopher J Moran Journal: J Neurointerv Surg Date: 2012-05-03 Impact factor: 5.836
Authors: Robert J McDonald; Jennifer S McDonald; David F Kallmes; Giuseppe Lanzino; Harry J Cloft Journal: Interv Neuroradiol Date: 2015-02 Impact factor: 1.610
Authors: Senka Runjaic; Jerah D Nordeen; Matthew W Soto-Arenall; Gretchen S Johns; David Miller; Benjamin Brown; William D Freeman Journal: J Vasc Interv Neurol Date: 2017-01
Authors: Yasha Kayan; Josser E Delgado Almandoz; Jennifer L Fease; Kira Tran; Anna M Milner; Jill M Scholz Journal: Neuroradiology Date: 2015-11-28 Impact factor: 2.804